

Transasia Biomedicals launches fully automated Analyzer

24 March 2015 | News | By BioSpectrum Bureau

Transasia Biomedicals launches fully automated Analyzer



Singapore: Transasia Bio-Medicals, India's leading invitro diagnostic company has announced the launch of HbA1c & HbA2/F-Fully Automated Analyzer that can routinely monitor glycemic control in patients with diabetes mellitus.

The new Analyzer comprises of a HPLC with unique CLE technology. The patented CLE technology enables complete elimination of labile glycohemoglobin thereby ensuring accurate HbA1c results, said Transasia in its press release. High levels of glycohemoglobin is directly related to elevated risks of diabetes complications.

India has earned the dubious distinction of being the 'Next Diabetes Capital of the world.' It is estimated that millions of diabetics in India are carrying the disorder and hence having complications of uncontrolled diabetes. The new Analyzer will help in early detection and easy estimation of glycohemoglobin levels.

Transasia Bio-Medicals has fortified its presence, being recognized as India's top manufacturer and exporter of diagnostic instruments and reagents in over 100 countries. Transasia has over 45,000 installations across India, with a vast network of more than 150 service engineers, 350+ sales and marketing team, 14 zonal offices, and 350+ Distributors.